These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
772 related articles for article (PubMed ID: 16294273)
1. Dominant negative N-cadherin inhibits osteoclast differentiation by interfering with beta-catenin regulation of RANKL, independent of cell-cell adhesion. Shin CS; Her SJ; Kim JA; Kim DH; Kim SW; Kim SY; Kim HS; Park KH; Kim JG; Kitazawa R; Cheng SL; Civitelli R J Bone Miner Res; 2005 Dec; 20(12):2200-12. PubMed ID: 16294273 [TBL] [Abstract][Full Text] [Related]
2. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637 [TBL] [Abstract][Full Text] [Related]
3. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644 [TBL] [Abstract][Full Text] [Related]
4. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286 [TBL] [Abstract][Full Text] [Related]
5. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2. Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755 [TBL] [Abstract][Full Text] [Related]
7. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. Spencer GJ; Utting JC; Etheridge SL; Arnett TR; Genever PG J Cell Sci; 2006 Apr; 119(Pt 7):1283-96. PubMed ID: 16522681 [TBL] [Abstract][Full Text] [Related]
8. Vitamin D(3) augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter. Kitazawa R; Kitazawa S Biochem Biophys Res Commun; 2002 Jan; 290(2):650-5. PubMed ID: 11785948 [TBL] [Abstract][Full Text] [Related]
9. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. Kondo H; Guo J; Bringhurst FR J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438 [TBL] [Abstract][Full Text] [Related]
10. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996 [TBL] [Abstract][Full Text] [Related]
11. Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells. Chung H; Kang YS; Hwang CS; Moon IK; Yim CH; Choi KH; Han KO; Jang HC; Yoon HK; Han IK J Korean Med Sci; 2001 Dec; 16(6):769-73. PubMed ID: 11748360 [TBL] [Abstract][Full Text] [Related]
12. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically. Valverde P; Tu Q; Chen J J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638 [TBL] [Abstract][Full Text] [Related]
13. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo. Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094 [TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342 [TBL] [Abstract][Full Text] [Related]
15. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398 [TBL] [Abstract][Full Text] [Related]
16. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. Ikeda F; Nishimura R; Matsubara T; Tanaka S; Inoue J; Reddy SV; Hata K; Yamashita K; Hiraga T; Watanabe T; Kukita T; Yoshioka K; Rao A; Yoneda T J Clin Invest; 2004 Aug; 114(4):475-84. PubMed ID: 15314684 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185 [TBL] [Abstract][Full Text] [Related]